Ferroptosis: Biochemistry and Biology in Cancers

Zhiyuan Shi1, Lei Zhang2, Jianzhong Zheng1, Huimin Sun3* and Chen Shao1*

1 Department of Urology, Xiang’an Hospital of Xiamen University, Xiamen, China, 2 School of Public Health, Xiamen University, Xiamen, China, 3 Clinical Central Research Core, Xiang’an Hospital of Xiamen University, Xiamen, China

The challenge of eradicating cancer is that cancer cells possess diverse mechanisms to protect themselves from clinical strategies. Recently, ferroptosis has been shown to exhibit appreciable anti-tumor activity that could be harnessed for cancer therapy in the future. Ferroptosis is an iron-dependent form of regulated cell death that is characterized by the oxidization of polyunsaturated fatty acids (PUFAs) and accumulation of lipid peroxides. Ferroptosis has been closely correlated with numerous biological processes, such as amino acid metabolism, glutathione metabolism, iron metabolism, and lipid metabolism, as well as key regulators including GPX4, FSP1, NRF2, and p53. Although ferroptosis could be involved in killing various cancer cells, multiple aspects of this phenomenon remain unresolved. In this review, we summarize the biochemistry and biology of ferroptosis in diverse cancers and discuss the potential mechanisms of ferroptosis, which might pave the way for guiding cancer therapeutics.

Keywords: ferroptosis, cancers, amino acid metabolism, iron metabolism, lipid metabolism

INTRODUCTION

Cancer has been widely recognized as the second leading cause of death worldwide (1). According to recent statistics on cancers in 185 countries, there were 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and 10 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) worldwide in 2020 (2). Although several therapeutic strategies such as surgery, radiotherapy, chemotherapy, ablation, and organ transplantation have been utilized to fight against cancer, many malignant cancers still do not show satisfactory results after treatment. The two major causes of cancer-related death are metastasis and recurrence of tumors; therefore, pinpointing mechanistic details of the pathways by which cancer cell death occurs is crucial for identifying treatment strategies and guiding clinical therapy.

Ferroptosis is defined as an iron-dependent form of nonapoptotic cell death (3), and is characterized by oxidation of polyunsaturated fatty acids (PUFAs) and accumulation of lipid peroxides. Cells undergoing ferroptosis cannot be rescued by chemical or genetic inhibitors of apoptosis or necroptosis, which indicates that ferroptosis is a distinct form of cell death (4). Ferroptosis has been investigated in many human diseases, such as neurodegenerative diseases [including Parkinson’s disease (5, 6), Alzheimer’s disease (7, 8), Friedreich’s ataxia (9), and Huntington’s disease (10)], organ injury [including hepatic damage (11, 12), brain injury (13–15), spinal cord injury (16, 17), and kidney injury (18–20)], organ fibrosis (21–23), cardiovascular diseases (24, 25), and gynecological diseases (26–28). Recently, an increasing number of studies on ferroptosis have been conducted in diverse cancers as ferroptosis is gradually being recognized as a
potential form to eliminate cancer cells. In this review, we discuss the mechanism of ferroptosis and its molecular regulation in various cancers.

OVERVIEW OF IDENTIFICATION OF FERROPTOSIS

In 2012, the concept of ferroptosis was first described by Scott J. Dixon (a member of the Brent R. Stockwell group) and his collaborators who described the characteristics of ferroptosis (3). Ferroptosis, a novel type of regulated cell death (RCD), is a unique form of intracellular iron-dependent peroxidation of PUFA-containing phospholipids (PLs), and is morphologically, biochemically, and genetically distinct from other forms of RCD including apoptosis, autophagy, and necroptosis. Cells undergoing ferroptosis show unique hallmarks including rupture of cellular membranes, smaller mitochondria with increased mitochondrial membrane density, reduced/vanished mitochondria cristae, rupture of outer mitochondrial membranes, and a normal nucleus (29).

Early Studies Related to Ferroptosis

In 1955, Eagle et al. first found that human uterine carcinoma HeLa cells cultured without cystine exhibited a unique microscopic morphology that was different than that resulting from deprivation of other amino acids (30). They also found that cells cultured in cystine-free medium failed to grow but could be restored by supplementing them with glutathione (GSH) (31, 32). In 1977, Bannai et al. showed that cystine starvation of human lung fibroblasts resulted in rapid reduction of GSH and subsequent cell death; however, cell death could be rescued by the addition of the lipophilic antioxidant α-tocopherol (a component of vitamin E) (33). These results implied that cystine could sustain the intracellular level of GSH and that there might be an accumulation of reactive oxygen species (ROS) that could be prevented by lipophilic antioxidants.

In 1965, two separate research teams both identified lipid peroxidation as a prime cause of cellular damage in rat liver (34, 35). In the 1980s, lipid peroxidation was considered to be one of the main forms of oxidative damage via the destruction of unsaturated lipid components of cell membranes and lipoproteins in some pathologies (36, 37). Nonetheless, these discoveries were considered as mechanisms of cellular damage at that time.

Conceptualization of Ferroptosis

Brent R. Stockwell and members tried to screen small molecules that could selectively kill cells overexpressing the oncogenic mutant HRAS. In 2003, they identified a novel compound that they named “erastin”, and explored the effect of erastin in engineering tumor cells. However, they found that no characteristics of apoptosis occurred, such as caspase activation, cleavage of caspase substrates, annexin V staining, and morphological changes in the nucleus (38). In 2007, they further reported that erastin induced the formation of oxidative species and subsequent death through an oxidative nonapoptotic mechanism, and that the cell death induced by erastin could be suppressed by α-tocopherol (39). In 2008, they reported yet another small compound, Ras selective lethal 3 (RSL3), which induced a similar iron-dependent non-apoptotic cell death in oncogenic RAS-harboring cancer cells, which could also be suppressed by both α-tocopherol and desferrioxamine mesylate (DFOM) (40). In 2011, the authors distinguished erastin- and RSL3-induced cell death from the mechanism of action of other cell death inducers (41). In 2012, they named this phenomenon of erastin-induced iron-dependent cell death as ferroptosis (3).

MECHANISMS OF FERROPTOSIS

As an increasing number of groups actively investigate ferroptosis, numerous mechanisms have been found to be involved in ferroptosis, such as amino acid metabolism, GSH metabolism, iron metabolism, and lipid metabolism (Figure 1 and Table 1).

Amino Acid and GSH Metabolism

GSH functions as a cofactor of GSH peroxidase 4 (GPX4, discussed in detail below) in lipid metabolism; thus, the synthesis of GSH regulates ferroptosis. GSH is synthesized with three substrates, namely glutamate, cysteine, and glycine, in two steps. The initial and limiting step is the combination of glutamate and cysteine to form GluCys in the presence of glutamate-cysteine ligase (GCL, previously known as γ-glutamyl-cysteine synthetase) utilizing ATP. Then, GluCys combines with glycine to yield GSH, which is catalyzed by GSH synthetase (GSS) in the presence of ATP. Buthionine sulfoximine (BSO) is a small molecular inhibitor of GCL known to indirectly inhibit the enzymatic activity of GPX4 (42). The pentose phosphate pathway (PPP) generates NADPH, which is essential for preserving the cellular levels of GSH. Inhibition of the PPP and silencing of two PPP enzymes, glucose-6-phosphate dehydrogenase (G6PD) and phosphoglycerate dehydrogenase (PGD), hinders erastin-induced ferroptosis in human lung cancer cells (3).

The heterodimeric amino acid antiporter system Xc− located on the cell surface consists of a twelve-pass transmembrane transporter protein solute carrier family 7 member A11 (SLC7A11, also known as xCT) and a single-pass transmembrane regulator protein SLC3A2 (4F2hc), both of which are linked by a disulfide bridge (59). It is a Na+-independent cystine/glutamate antiporter that imports one molecule of extracellular cystine by exporting the equivalent molecule of intracellular glutamate, followed by the conversion of the cystine to cysteine by disulfide bond breakage. Therefore, system Xc− inhibition will result in cysteine depletion in cells. In this context, several suitable compounds and their derivatives have been reported by researchers. Erastin, an oncogenic RAS-selective lethal small molecule, is the first compound reported to trigger ferroptosis by suppressing system Xc− (3). Although the precise mechanism underlying erastin-mediated inhibition of
SLC7A11-mediated cysteine import remains unclear, it is agreed that erastin most likely inhibits SLC7A11 directly (60). The erastin derivatives imidazole ketone erastin (IKE) and piperazine erastin (PE) have been shown to induce ferroptosis (42, 61). Sulfasalazine (SAS), a medicine for arthritis, shows low potential inhibition of system Xc at high concentrations (62). Sorafenib, an inhibitor of oncogenic kinases and approved by the Food and Drug Administration (FDA) as an anticancer drug, induces ferroptosis in different cancer cell lines (63–65). A high extracellular concentration of glutamate could initiate ferroptosis.

FIGURE 1 | An overview of ferroptosis. ARE, antioxidant response element; BSO, buthionine sulfoximine; CoQ10, coenzyme Q10; CUL3, cullin2; DFO, deferoxamine; DFOM, desferrioxamine mesylate; DMT1, divalent metal transporter 1; FPN, ferroportin; FSP1, ferroptosis suppressor protein 1; GCL, glutamate-cysteine ligase; GLS2, glutaminase 2; GPX4, GSH peroxidase 4; GSH, glutathione; GSS, glutathione synthetase; 4-HNE, 4-hydroxynonenal; HO, hydroxyl radical; IKE, imidazole ketone erastin; KEAP1, Kelch-like ECH-associated protein 1; LIP, labile iron pool; LOX, lipoxygenase; MDA, malondialdehyde; MSRB2, methionine-R-sulfide reductase B2; NCOA4, nuclear receptor coactivator 4; NRF2, nuclear factor erythroid 2-related factor 2; PE, piperazine erastin; PL, phospholipid; PL*, PL radical species; PLOH, PL hydroperoxide; RSL3, RAS synthetic lethal 3; SAS, sulfasalazine; SCARA5, scavenger receptor class A member 5; sMAF, small Maf; SLC1A5, solute carrier family member 1 member A5; STEAP, six-transmembrane epithelial antigen of prostate; TFR1, transferrin receptor 1; ZIP8, Zrt- and Irp-like protein 8.
TABLE 1 | Regulators of ferroptosis.

| Gene                  | Protein                                      | Effect                                      | References |
|-----------------------|----------------------------------------------|---------------------------------------------|------------|
| Amino acid and GSH metabolism |                                              |                                             |            |
| **GCL**               | Glutamate-cysteine ligase                    | Inhibition induces ferroptosis              | 42         |
| **G6PD**              | Glucose-6-phosphate dehydrogenase            | Knockdown hinders erastin-induced ferroptosis | 3          |
| **PGD**               | Phosphoglycerate dehydrogenase               | Knockdown hinders erastin-induced ferroptosis | 3          |
| SLC7A11               | Solute carrier family 7 member A11, xCT      | Inhibition induces ferroptosis              | 3          |
| GLS2                  | Glutaminase 2                                | Inhibition induces ferroptosis              | 43         |
| GPT1                  | Glutamic-oxaloacetic transaminase 1          | Modulates ferroptosis in the mitochondrial tricarboxylic acid cycle | 45         |
| Iron metabolism       |                                              |                                             |            |
| TFR1                  | Transferrin receptor 1                       | Knockdown suppresses ferroptosis            | 46         |
| DMT1                  | Divalent metal transporter 1                 | Inhibition promotes ferroptosis             | 47         |
| NCOA4                 | Nuclear receptor coactivator 4               | Knockdown suppresses ferroptosis            | 48         |
| FPN                   | Ferroportin                                  | Knockdown suppresses ferroptosis            | 49         |
| Lipid metabolism      |                                              |                                             |            |
| ACSL4                 | Acyl-CoA synthetase long-chain family member 4 | Knockdown suppresses ferroptosis            | 50; 51     |
| LPCAT3                | Lysophosphatidylcholine acyltransferase 3    | Knockdown suppresses ferroptosis            | 50; 51     |
| LOX                   | Lipoxygenase                                 | Promotes ferroptosis                        | 4          |
| Key regulators        |                                              |                                             |            |
| GPX4                  | GSH peroxidase 4                             | Inhibition induces ferroptosis              | 52         |
| FSP1                  | Ferroptosis suppressor protein 1             | Induces ferroptosis resistance              | 53; 54     |
| NFE2L2                | Nuclear factor erythroid 2-related factor 2   | Knockdown suppresses ferroptosis            | 55         |
| TPS3                  | p53                                          | Promotes ferroptosis                        | 56; 57     |

### Iron Metabolism

The first observation that iron participates in the process of ferroptosis originated from reports that iron chelators could prevent cell death induced by cystine deprivation (considered as ferroptosis now) in 1996 (69). The biological function of iron is mainly dependent on its ability to accept and donate electrons while switching among the ferrous bivalent (Fe^{2+}), ferric trivalent (Fe^{3+}), and ferryl tetravalent (Fe^{4+}) states by catalyzing various biochemical reactions (70). At the cellular level, three forms of ROS, including superoxide (O_{2}^{-}), hydrogen peroxide (H_{2}O_{2}), and hydroxyl radical (HO•), are related to iron in redox reactions. O_{2}^{-} and H_{2}O_{2} are respectively known as single and double univalent reductions of molecular oxygen (O_{2}) respectively, while the most chemically active ROS is HO•, which can cause nonspecific oxidation that destroys biological molecules such as lipids. In the Fenton reaction, Fe^{2+} is oxidized to Fe^{3+} by a reaction with H_{2}O_{2}, while the electron transfers to H_{2}O_{2} to form HO• (71). Conversely, Fe^{3+} could be reduced back to Fe^{2+} through reaction with O_{2} while HO• loses an electron to form O_{2}, which is known as the Haber-Weiss reaction (72).

Sufficient levels of free intracellular iron is a necessity for triggering ferroptosis. There are four following routes for cells to import iron (73). The most crucial route is mediated by transferrin and its partner, the transferrin receptor 1 (TFR1). Transferrin, a type of globulin mainly synthesized by the liver and released into the serum, has an excellent ability to chelate and donate iron to TFR1 complex at the low pH conditions of endocytic vesicles and reduced to Fe^{2+} by the six-transmembrane epithelial antigen of...
prostate (STEAP) family (73, 74). Fe^{2+} is then released into the cytoplasm via the divalent metal transporter 1 (DMT1) and participates in establishing the intracellular labile iron pool (LIP) (75). Meanwhile, apo-transferrin and TFRI remain bound until the complex is recycled back to the plasma membrane, followed by apo-transferrin releases (76). The second route is directly assimilating the free iron unbound by transferrin; however, each iron transporter only transports Fe^{2+}. Therefore, Fe^{3+} is first reduced to Fe^{2+} by several types of ferrireductases (e.g., STEAP, cytochrome B reductase 1, and ferric chelate reductase 1), and the Fe^{2+} is directly transported into cells by cellular membrane transporters including DMT1, Zrt- and Irt-like protein 8 (ZIP8), and ZIP14 (73). The third pathway involves the uptake of hemoglobin-containing porphyrin-bound Fe^{2+}, especially in macrophages (77). The fourth mechanism involves the assimilation of the iron-storage protein ferritin by its cellular membrane receptors such as the scavenger receptor class A member 5 (SCARA5) found in embryos and in the kidney (78).

After iron uptake, the intracellular iron can be utilized, stored, and exported. In terms of utilization, mitoferrin 1 and 2 specially transport iron into the mitochondria to assist with cellular respiration and synthesis of Fe-S clusters and heme (79). There are two forms of intracellular storage, LIP and ferritin. LIP cooperates with ceruloplasmin or hephaestin, is mainly responsible for transporting Fe^{2+} out of cells (82). Ferritin is an iron-sequestering protein that contains up to 4500 iron atoms and possesses multiple functions in iron delivery, cell proliferation, angiogenesis, and immunosuppression (80). Ferritin can also be degraded to release free iron via the nuclear receptor coactivator 4 (NCOA4), a process termed as "ferritinophagy" (81). In terms of iron export, ferroportin (FPN, i.e., SLC40A1), once known as the only iron efflux pump that cooperates with ceruloplasmin or hephaestin, is mainly responsible for transporting Fe^{2+} out of cells (82). Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in HepG2 and Hep3B cells, and depletion of ceruloplasmin results in the accumulation of intracellular Fe^{2+} and lipid ROS and promotes erastin- and RSL3-induced ferroptotic cell death (83). In addition, prominin 2 promotes the formation of ferritin-containing multivesicular bodies and exosomes that transport iron out of the cell to facilitate ferroptosis resistance in breast cancer (84).

Treating cells without transferrin or with TFR RNAi could not lead to significant ferroptotic cell death, indicating that an external iron source is required for ferroptosis (46). STEAP1 and STEAP2 are highly expressed in various human cancer types, such as the colon, breast, cervix, prostate, pancreas, bladder, ovary, testis, and Ewing sarcoma (85–87). STEAP3 is overexpressed in malignant gliomas and induces cancer epithelial–mesenchymal transition (EMT) (88). STEAP4 is activated under hypoxic conditions, leading to mitochondrial iron imbalance and enhanced ROS production (89). FPN is dramatically suppressed in many cancer types (90), indicating that there might be abundant iron in cancer cells. Reduced FPN levels in triple-negative breast cancer (TNBC) cells stimulate proliferation and EMT (91). Hepcidin, synthesized by tumors or the liver, facilitates FPN degradation and contributes to cancer proliferation and progression (92). Proteins involved in raising the levels of intracellular iron (TFRI, DMT1, and hepcidin) are extensively upregulated in tumor cells, whereas proteins suppressing intracellular iron accumulation (FPN and hephaestin) are downregulated (93).

### Lipid Metabolism

The fact that ferroptosis is driven by peroxidation of PUFAs, and not monounsaturated fatty acids (MUFAs) or deuterated PUFAs, was confirmed by Brent R. Stockwell and coworkers in 2016 (4). As is known to all, PUFAs, as well as essential fatty acids, could not be physiologically synthesized and must be obtained from food. PUFAs are defined as a fatty acid containing at least two -CH=CH- groups, such as linoleic acid, linolenic acid, and arachidonic acid (AA). PLs, the basic components of the cellular membrane, are classified as glycerophospholipids and sphingomyelin. The predominant fatty acid moiety in sphingomyelin is saturated fatty acids or MUFAs, whereas glycerophospholipids contain an esterified C16 or C18 saturated fatty acid at C-1, an esterified C18 to C20 unsaturated fatty acid (e.g., AA) at C-2, and a phosphatidic ester group at C-3 of the glycerol backbone. The incorporation of de novo synthesized fatty acids into PLs requires acyl-CoA synthetases (ACSs) that convert long-chain fatty acids to acyl-CoA and lysophospholipid acyltransferases (LPLATs) that, in turn, catalyze the subsequent reacylation step to form PLs (94). For instance, lipidomic studies suggest that phosphatidylethanolamines containing AA or arachidonic acid (AdA), are key PLs that undergo oxidation and drive the occurrence of ferroptosis (50, 51). ACS long-chain family member 4 (ACSL4) preferentially converts AA to acylated AA, and lysophosphatidylcholine acyltransferase 3 (LPCAT3) subsequently catalyzes the incorporation of acylated AA into the PL (51, 95).

There are two mechanisms of lipid peroxidation, the non-enzymatic free radical chain reaction and the enzymatic process. Compared with the tightly controlled enzymatic lipid peroxidation, the free radical chain reaction involving Fenton chemistry is poorly controlled. There are three types of lipid oxidation enzymes, namely cyclooxygenase (COX), cytochrome P450 (CYP), and lipoxygenase (LOX). COXs synthesize lipid endoperoxides and are partially responsible for the peroxidation of linoleic acid, while CYPs synthesize epoxyeicosatrienoic acids and LOXs contribute predominantly to the synthesis of lipid hydroperoxides.

Nonenzymatic lipid peroxidation involves the oxidation of PUFAs, initiated by ROS. In unsaturated acyl chains, the allylic hydrogen atoms, i.e., the hydrogen atoms on methylene groups adjacent to double bonds, exhibit low carbon-hydrogen (C-H) bond energies, while the hydrogen atoms located on methylene between two double bonds (bis-allylic hydrogen atoms) have even lower C-H bond energies, thus bis-allylic hydrogen atoms can be abstracted by ROS, forming PL radical species (PL•) with the radical centered on the allylic carbon atom (96). Therefore, PUFAs are highly susceptible to oxidative damage due to the
existence of bis-allylic hydrogen atoms that saturated fatty acids and MUFAs do not possess. According to previous reports (96, 97), in the presence of HO\(^-\) derived from the Fenton reaction, the PUFA of PL donates a hydrogen atom to HO\(^-\) and becomes a carbon-centered PL\(^-\) that further reacts with intracellular molecular O\(_2\) to form a PL peroxyl radical (PLOO\(^-\)). Next, with the participation of PUFA moiety from another PL, PLOO\(^-\) abstracts a hydrogen atom and subsequently converts to PL hydroperoxide (PLOOH) accompanied with a new PL\(^-\). PLOOH is cleaved in the presence of Fe\(^{2+}\) to form the PL alkoxyl radical (PLO\(^-\)) that reacts with PUFA of another PL to form PL alcohol (PLOH) and a new PL\(^-\), followed by another lipid radical chain reaction.

The enzymatic pathway mainly involves iron-containing LOXs, which can catalyze the site-specific oxidation of PUFAs in a controlled manner. LOXs are classified based on their regioselectivity (e.g., the number of carbon atoms subjected to deoxygenation) and stereoselectivity (“S” or “R”) (98). There are six LOX isoforms discovered in humans, namely 5-LOX, 12-LOX, 12R-LOX, 15-LOX-1, 15-LOX-2, and e-LOX3, ranging from 662 to 711 amino acids and sharing 44% of their sequence identity (99). Encoded by the ALOX5 gene, 5-LOX could oxidize AA at C-5 to form 5-hydroperoxyicosatetraenoic acid (5-HpETE), which is subsequently converted to leukotriene A\(_4\) (LTA\(_4\)) by 5-LOX (100, 101). Once 5-LOX is activated, it migrates to the nuclear membrane where it associates with two additional proteins: the 5-LOX activating protein (FLAP) and cytosolic phospholipase A\(_2\) (cPLA2) (102). cPLA2 is responsible for cleaving AA from PLs to increase substrate availability for 5-LOX. Although the exact function of FLAP is still unclear, pharmacological inhibition of FLAP function prevents oxidation of endogenous AA by 5-LOX, which demonstrates the necessary role of FLAP in lipid peroxidation (103).

Compared with 5-LOX, which oxidizes hydrolyzed arachidonoyl groups of PLs by cPLA2, 12-LOXs and 15-LOXs, encoded by ALOX12/ALOX12B and ALOX15/ALOX15B, respectively, directly oxidize AA to synthesize 12-HpETE and 15-HpETE, which are rapidly reduced to their corresponding hydroxides and hepoxilins (104). Meanwhile, 12-LOXs and 15-LOXs can also oxidize linoleic acid to generate 13-hydroperoxyoctadecadienoic acid (13-HpODE), which is subsequently reduced to 13-HODE (101). Docosahexaenoic acid (DHA) is also a substrate for 15-LOX-1, which metabolizes the conversion of ω-3 fatty acid to 17-hydroperoxydocosahexaenoic acid (17-HpDHA), which is rapidly transformed into resolvins and protectins (105).

Lipid peroxidation of membranes substantially alters the physical properties of lipid bilayers in terms of disrupted ion gradients, decreased membrane fluidity, slower lateral diffusion, and increased membrane permeability (106). There exist two mechanisms for eliminating lipid peroxides from cells without the generation of new radicals. GPXs, especially GPX4, are crucial regulators for reducing lipid peroxides to corresponding alcohols by utilizing GSH as a cofactor (107), thereby limiting the transition metal-dependent formation of toxic radicals (e.g., PLO\(^-\)). Another mode of degradation involves the conversion of lipid peroxides to aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which should undergo multiple oxidation steps. However, there is still no definitive consensus about the metabolic route that predominantly contributes to the degradation of lipid peroxides among multiple biosynthesis routes (101). MDA could react with primary amines on proteins or DNA to form crosslinks. Moreover, excessive MDA generation within cells is associated with major human diseases including cancer (108). Decomposition of AAs and longer PUFAs generates 4-HNE, which contains three functional groups: (i) an electrophilic C=C double bond that is a Michael acceptor and that forms covalent adducts with nucleophilic amino acids; (ii) an aldehyde that can form Schiff base adducts with primary amines; and (iii) a hydroxyl group that can be oxidized to an electrophilic ketone (109). The electrophile 4-HNE has been widely studied as a signaling molecule that stimulates the cell cycle and cellular proliferation, along with investigation into its cytotoxic nature known to inhibit gene expression (110).

### Key Regulators of Ferroptosis

**GPX4**

According to phylogeny, the GPX family is divided into three groups: GPX1 and GPX2; GPX3, GPX5, and GPX6; GPX4, GPX7, and GPX8, and could also be classified as selenocysteine-containing GPXs and cysteine-containing GPXs depending on whether the active center contains Sec or Cys (111). GPX4, i.e., PL hydroperoxide GPX, is the second selenoperoxidase to be isolated and is regarded as a peroxidation-inhibiting protein after the identification of GPX1 (112). GPX4 is the only GPX for which PL hydroperoxides in membranes and protein-thiol groups can act as oxidizing and reducing substrates, respectively, under conditions of GSH deprivation (113). It was first isolated and purified from pig liver in 1982, and was identified to confer protection to liposomes and biomembranes from iron-catalyzed lipid peroxidation (114). The human GPX4 was isolated from human liver in 1994 (115). GPX4, containing 170 amino acids, has a typical thioredoxin motif consisting of four \(\beta\)-helices that are localized at the protein surface and seven \(\beta\)-strands, five of which form a central \(\beta\)-sheet (116). The catalytic triad, consisting of selenocysteine (U46), glutamine (Q81), and tryptophan (W136) residues, is localized at the protein surface, and mutations in any of these residues could lead to the inactivation of GPX4 (117). For instance, replacement of selenocysteine with cysteine could diminish the activity of GPX4 by 90% and strengthen its sensitivity to redox stress (118). GPX4 reduces lipid peroxides to the corresponding alcohols via oxidation of its active site selenol (Se-H) to selenenic acid (Se-OH), which is then reduced by two equivalents of GSH to the active Se-H (101).

RSL3 has four diastereomers, but only 1S,3R-RSL3 can induce ferroptosis by suppressing the enzymatic activity of GPX4 via covalent modifications without affecting intracellular GSH levels (42, 119). Conversely, overexpression of GPX4 could prevent RSL3-induced ferroptotic cell death (42). RSL3 induces ferroptosis in colorectal cancer cells due to decreased expression of GPX4 and both increased levels of ROS and
cellular LIP (52). In addition to RSL3, ML162, ML210, and altretam (an FDA-approved anticancer agent) can also induce ferroptosis by suppressing GPX4 (120). Inducible GPX4 inactivation could also lead to 12/15-LOX-derived lipid peroxidation as a specific downstream event, which indicates that GPX4 could prevent cell death by inhibiting 12/15-LOX (113). FIN56, derived from CIL56, exhibits greater potency and better oncogenic RAS selectivity than CIL56 (121). FIN56, derived from CIL56, exhibits greater potency and better oncogenic RAS selectivity than CIL56 (121). FIN56 induces ferroptosis by degrading GPX4 protein, instead of downregulating GPX4 mRNA transcription and subsequent synthesis of GPX4 protein, and simultaneously causes depletion of mevalonate-derived coenzyme Q$_{10}$ (CoQ$_{10}$), which is an electron carrier in the mitochondrial respiratory chain and an endogenous antioxidant. FINO2, an endoperoxide-containing 1,2-dioxolane, can initiate ferroptosis selectively in engineered cancer cells, such as renal cancer cell Caki-1 and fibrosarcoma cell HT-1080 (122). FINO2 does not inhibit the antipporter system X$_{c}$; instead, it directly represses the enzymatic activity of GPX4, or depletes GPX4 and CoQ$_{10}$. However, it can directly oxidize iron and indirectly suppresses the enzymatic function of GPX4, ultimately causing widespread lipid peroxidation. The side effects of statin treatment could be attributed to reduced levels of GPX4 in some tissues (123), while the decreased incidence of several cancers on statin consumption (124) and the loss of GPX4 detected in some cancer cells with statin treatment could be ascribed to repression of GPX4 synthesis (125). Further, statin treatment has also been shown to deplete CoQ$_{10}$ (126).

**FSP1**

Ferroptosis suppressor protein 1 (FSP1), previously known as apoptosis-inducing factor mitochondrial-associated 2 (AIFM2), was recently identified as a ferroptosis resistance factor (54). Although GPX4 is essential for cancer cells to escape from ferroptosis, inhibition of GPX4 fails to trigger ferroptosis in some cancer cells regardless of ACSL4 expression, suggesting the existence of additional mechanisms of ferroptosis resistance. The anti-ferroptotic function of FSP1 is independent of cellular GSH level, GPX4 activity, ACSL4 expression, and oxidizable fatty acid content, showing that FSP1 does not interfere with canonical ferroptosis mechanisms. Moreover, p53 status does not affect FSP1 expression. FSP1 expression is positively correlated with ferroptosis resistance in many cancer cell lines (127). FSP1 can prevent PL peroxidation and its suppression has been shown to be enhanced in the presence of both CoQ$_{10}$ and α-tocopherol (54). In the presence of FSP1, CoQ$_{10}$ was reduced to CoQ$_{20+}$H$_2$ using NADPH to inhibit the propagation of PL peroxidation. Inhibition of FSP1 can robustly sensitize cells to RSL3-induced ferroptosis (53, 54).

**NRF2**

Nuclear factor erythroid 2-related factor 2 (NRF2) encoded by NFE2L2 is a transcription factor that consists of 605 amino acids and contains seven conserved homology domains termed as Neh1-Neh7 (128, 129). Neh2 is the major regulatory domain that has two binding motifs known as DLG and ETGE, both of which help to regulate NRF2 stability by interacting with the Kelch domains of the E3 ubiquitin ligase Kelch-like ECH-associated protein 1 (KEAP1), which is the most notable negative regulator of NRF2 and contains a number of cysteine residues (including C151, C273, and C288) that act as electrophilic attack centers (130). Under physiological conditions, NRF2 is maintained at low levels in normal tissues because of KEAP1-dependent ubiquitination (130). KEAP1 acts as an adaptor for NRF2 binding to the KEAP1-cullin 3-ring box protein 1 (KEAP1-CUL3-RBX1) E3 ubiquitin ligase complex, which targets NRF2 for rapid proteasomal degradation (129). During increased oxidative stress, or if KEAP1, CUL3, or NRF2 are mutated, NRF2 can no longer be ubiquitylated and degraded, and the newly translated NRF2 transfers to the nucleus and activates transcription of anti-oxidant response element (ARE)-containing genes, many of which play a key role in preventing the initiation of ferroptosis (131). RSL3 or ML-162 treatment increases the expression of p62 and NRF2 in chemo-resistant HN3R and HN3-rslR cells, inactivates KEAP1, and increases the expression of the phospho-protein kinase R-like endoplasmic reticulum kinase (p-PERK)-activating transcription factor 4 (ATF4)-serpin 2 (SESN2) (132). NRF2 inhibition could reverse the resistance of cisplatin-resistant HNC cells to artemisinin-induced ferroptosis (55). With regard to other Neh domains, Neh1 known as a DNA binding domain enhances NRF2 transcriptional activation (133). The Neh3, Neh4, and Neh5 domains are known as trans-activation domains of NRF2 (134–136). Neh6, a serine-rich domain, negatively modulates NRF2 stability (137), and Neh7 has been shown to interact with the nuclear receptor retinoid X receptor α (RXRα), which inhibits the transcription of NRF2 target genes (138).

The genetic products of NRF2 activation can be categorized functionally with respect to their involvement in three cellular processes consisting of iron/metal metabolism, intermediate metabolism, and GSH synthesis/metabolism. Resistant melanoma cells can efficiently activate NRF2 (which upregulates the early ferroptotic marker GSH-specific γ-glutamylcyclotransferase 1 (CHAC1) in an endoplasmic reticulum (ER) stress-independent manner) and aldo-keto reductase AKR1C1-3 (which degrades lipid peroxides generated by 12/15-LOX), which could cumulatively result in resistance to ferroptotic cell death (139). NRF2 targets many genes involved in iron/metal metabolism, such as the light chain and heavy chain of ferritin (FTL/FTH1), FPN, heme oxygenase-1 (HO-1), biliverdin reductase A and B (BLVRA/B), ferrochelatase (FECH), ATP-binding cassette sub-family B member 6 (ABCB6), and SLC48A1, which are all regulated by NRF2 (140–145). In terms of the relationship between NRF2 and intermediate metabolism, NRF2 targets are involved in lipid metabolism (i.e., peroxisome proliferator-activated receptor γ, PPARγ), the reduction of aldehydes and ketones to their alcohol forms (i.e., aldo-keto reductases, AKR1C-3, AKR1B1, and AKR1B10), and glucose metabolism/NADPH regeneration (i.e., G6PD) (146–149). Considering GSH synthesis/metabolism, numerous processes are under the control of NRF2, such as GSH metabolism (i.e., GCL, GSS, and SLC7A11), redox (i.e., GSH-S-transferases pi 1 and α 1, GSTP1 and GSTA1; peroxiredoxin 1
and 6, PRDX1 and PRDX6; and thioredoxin reductase, TXNRD), and the reduction of lipid peroxides (i.e., GPX4) (150–152). As mentioned above, some of these progresses have been confirmed to be involved in ferroptosis.

**p53**

The tumor suppressor gene TP53, regarded as the “guardian of the genome”, was first discovered in 1979 in a complex with the simian virus 40 large T antigen and has been widely studied in cancers (153). Many studies have suggested that p53 could act synergistically with established oncogenes to promote the conversion of normal tissues to tumors and lead to accelerated metastasis. The first evidence that p53 might act as a tumor suppressor was reported in 1984 (154). Subsequently, it was concluded that these previous experiments were performed not with wild-type p53, but with its mutated version (155). The mutant p53 is highly abundant in cancers, and it promotes tumorigenesis by disabling the function of the wild-type p53, as well as by “gain-of-function” processes such as the accumulation of p53 mutations, that augments the oncogenic capacity of the mutated p53 and delivers a stronger tumoral resistance against anti-cancer treatments (156, 157). Under normal conditions, the levels of p53 are low because of the E3 ubiquitin-protein ligase MDM2, which can target and degrade p53, while oncogene activation could prevent MDM2 binding to p53 and stimulate p53 acetylation (158). Although 42% of cases across 12 tumor types occur due to TP53 mutation, while oncogene activation could prevent MDM2 binding to p53, while oncogene activation could prevent MDM2 binding to p53 and stimulate p53 acetylation (158). Although 42% of cases across 12 tumor types occur due to TP53 mutation, the rate varies widely across diverse types of cancers (159).

Apart from the effects of p53 on apoptosis, autophagy, and the cell cycle, it also regulates ferroptosis via transcriptional or post-transcriptional mechanisms. Intriguingly, p53 can enhance or inhibit ferroptosis via different pathways. As to pro-ferroptosis, p53 promotes ferroptosis of MCF7 and U2OS cells due to SLC7A11 repression without affecting the expression of other p53 target genes involved in the cell cycle and apoptosis (56). p53 targets spermidine/spermine N1-acetyltransferase 1 (SAT1), which correlates with the expression of 15-LOX, and promotes the expression of SAT1 to induce ferroptosis (57). Depletion of p53 prevents nuclear accumulation of dipeptidyl peptidase-4 (DPP4) and triggers membrane-associated DPP4-mediated lipid peroxidation by binding to NADPH oxidase 1 (NOX1), which culminates in the ferroptosis of colorectal cancer cells. On the other hand, p53 mediates expression of the tumor suppressor cyclin-dependent kinase inhibitor 1A (CDKN1A/p21), which is a key mediator of p53-dependent cell cycle arrest after DNA damage, delays the onset of ferroptosis in response to cystine deprivation in cancer cells, and increases p53 expression by using the MDM2 inhibitor nutlin-3 that blocks erastin-induced ferroptosis in HT-1080 cells (58).

**FERROPTOSIS AND CANCER**

Here, different cancer groups are discussed in the context of ferroptosis, and the numerous inducers and inhibitors of ferroptosis, including drugs, genes, and RNA are listed in Table 2.

**Pharmaceuticals-Induced Ferroptosis**

Many clinical drugs have the ability to induce ferroptosis in cancer cells, which means that researchers need to comprehensively explore the potential mechanisms of these drugs. Artesunate, an anti-malarial drug, can specifically induce ferroptosis in pancreatic cancer cells without affecting pancreatic ductal epithelial cells (169). Artesunate also activates the ATF4-CHOP-CHAC1 cascade in DAUDI and CA-46 cells, and CHAC1 enhances artesunate-induced ferroptosis in Burkitt’s lymphoma cells (210). Dihydroartemisinin, a semisynthetic derivative of artemisinin, increases ROS levels in a dose-dependent manner and decreases the levels of both GPX4 and RAS in HEP-2 and CNE-1 cells (189). Dihydroartemisinin can also regulate the activity of the AMP-activated protein kinase (AMPK)/mTOR/p70S6k signaling pathway, thereby accelerating ferritin degradation, increasing LIP, promoting cellular ROS accumulation, and eventually triggering ferroptosis in acute myeloid leukemia cells (200). Several anti-inflammatory drugs have shown the potential to induce ferroptosis. Combinatorial treatment of auranofin and BSO can downregulate GPX4 and accumulate NRF2 and HO-1 (162). Ibuprofen induces ferroptosis in glioblastoma cells by downregulating the NRF2 signaling pathway (213). Acetaminophen can strengthen the sensitivity of erastin-induced ferroptosis by modulating the NRF2/HO-1 signaling pathway in non-small-cell lung cancer (NSCLC) (145). SAS can induce ferroptosis in breast cancer cells by upregulating TFRI and DMT1, especially in cells with low expression of estrogen receptors (47). The tranquilizer haloperidol promotes ferroptosis by accelerating iron accumulation, lipid peroxidation, and GSH depletion under erastin or sorafenib treatment in HepG2 and Huh-7 cells (160). The lysosome disruptor siramesine and the tyrosine kinase inhibitor lapatinib synergistically induce ferroptosis by increasing the expression of transferrin and decreasing the expression of FPN (188).

Many extracts from plants and herbs also exhibit anti-tumor effects by inducing ferroptosis. Ruscogenin can induce ferroptosis by improving ROS generation and trigger intracellular iron accumulation by upregulating transferrin and downregulating FPN (49). Piperlongumine can also induce ferroptosis in pancreatic cancer cells (171). Amentoflavone represses the expression of FTH by autophagy via activation of the AMPK/mTOR/p70S6K signaling pathway to trigger in vitro and in vivo ferroptosis in an autophagy-dependent manner (177). Typhaneoside, a major flavonoid found in the extract of Pollen Typhae, promotes the activation of the AMPK signaling pathway to contribute to ferritin degradation, ROS accumulation, and ferroptosis in Kas-1, HL-60, and NB4 cells (202). Pseudolaric acid B isolated from cortex pseudolaricis triggers ferroptosis in vivo and in vitro by upregulating TFRI, activating NOX4, and inhibiting SLC7A11 (178). Actinidia chinensis Planch (ACP) has been shown to increase the accumulation of ROS by inhibiting GPX4 and SLC7A11 to induce ferroptosis in HGC-27 cells (193). Dihydroisotanshinone I, a pure compound present in danshen, can induce ferroptosis by downregulating the expression of GPX4 both in vitro and in vivo (186). The extract of Betula etnensis Raf. and 6, PRDX1 and PRDX6; and thioredoxin reductase, TXNRD), and the reduction of lipid peroxides (i.e., GPX4) (150–152). As mentioned above, some of these progresses have been confirmed to be involved in ferroptosis.
(Birch Etna) promotes an oxidative cellular microenvironment resulting in HO-1-mediated ferroptosis of CaCo-2 cells (191). Erianin, a natural product isolated from Dendrobium chrysotoxum Lindl, induces ferroptotic cell death in lung cancer cells via Ca2+/calmodulin signaling (181).

Some new compounds are still being found by researchers. The novel compound ferroptocide, identified as an inhibitor of thioredoxin, could rapidly and robustly induce ferroptotic cell death and positively modulate the immune system in a breast cancer model (187). Phenethyl isothiocyanate, present in cruciferous vegetables, induces ferroptosis, autophagy, and apoptosis in K7M2 cells by activating the ROS-related mitogen-activated protein kinase (MAPK) signaling pathway (211).

### TABLE 2 | Inducers and inhibitors of ferroptosis in different cancers.

| Cancer                      | Inducer          | Reference(s) | Inhibitor          | Reference(s) |
|-----------------------------|------------------|--------------|--------------------|--------------|
| Hepatocellular carcinoma    | Auranofin        | 160;         | Ceruloplasmin      | 164;         |
|                             | BSO              | 161;         |                    | 165;         |
|                             | Haloperidol      | 162;         |                    | 166;         |
|                             | RB               | 163;         |                    | 83;          |
|                             | miRNA-214-3p     |              |                    | 167;         |
|                             |                  |              |                    | 168;         |
| Pancreatic cancer           | Artesunate       | 169;         |                    | 173;         |
|                             | Ruscogentin      | 170;         |                    | 174;         |
|                             | ARF6             | 49;          |                    | 175;         |
|                             | Piperlongumine   | 171;         |                    | 172;         |
| Glioma                      | Dihydroartemisin | 176;         | HSPA5              | 176;         |
|                             | Amentoflavone    | 177;         |                    | 179;         |
|                             | Pseudolic acid B | 178;         | cirRNA TTBK2       | 180;         |
| Lung cancer                 | Acetaminophen    | 181;         |                    | 182;         |
|                             | Erianin          | 146;         |                    | 183;         |
|                             |                  |              |                    | 184;         |
|                             |                  |              |                    | 185;         |
| Breast cancer               | SAS              | 186;         |                    | 187;         |
|                             | Siramesine       | 187;         |                    | 188;         |
|                             | Lapatinib        | 188;         |                    | 47;          |
|                             | Dihydroisotanshnhione I | | Ferroptocide | |
| Head and neck cancer        | RSL3             | 189;         | SLC7A11            | 190;         |
|                             | ML-162           | 132;         | CISH2              | 68;          |
|                             | Dihydroartemisin |              |                    |             |
| Colorectal cancer           | RSL3             | 191;         |                    | 192;         |
|                             | Bromelain        | 192;         |                    | 52;          |
|                             | Birch Etna       |              |                    |             |
|                             | Vitamin C        |              |                    |             |
| Gastric cancer              | ACP              | 193;         | miRNA-S22          | 195;         |
|                             | PG               | 194;         | miRNA-103a-3p      | 196;         |
|                             |                  |              |                    | 194;         |
| Melanoma                    | miRNA-9          | 197;         | AKR1C1-3           | 139;         |
|                             |                  |              |                    | 198;         |
|                             |                  |              |                    | 199;         |
| Leukemia                    | Dihydroartemisin | 200;         |                    | 201;         |
|                             | Typhaneoside     | 202;         |                    | 202;         |
|                             | HMGB1            | 203;         |                    | 204;         |
| Ovarian cancer              | TAZ              | 205;         | SCD1               | 206;         |
|                             |                  |              |                    | 207;         |
| Renal cell carcinoma        | HIF-2α           | 208;         | VHL                | 209;         |
|                             | TAZ              | 209;         |                    | 210;         |
|                             | MAPK             | 208;         |                    | 211;         |
| Lymphoma                    | Artesunate       | 210;         |                    | 212;         |
| Osteosarcoma                | Phenethyl iso thiocyanate | 212;        |                    |             |

ACP, Actinidia chinensis Planch; AKR1-3, aldo-keto reductase 1-3; ARF6, ADP-riboseylation factor 6; BSO, buthionine sulfoximine; CBS, cystathionine β-synthase; CDO1, cysteine dioxygenase 1; CDD1, CDGSH iron sulfur domain 1; DNAJB6, DNAJ/Hsp40 homolog subfamily B member 6; GDF15, growth/differentiation factor 15; GPR78, glucose-regulated protein 78; HIF-2α, hypoxia inducible factor 2α; HMGB1, high mobility group box 1; HPSA5, heat shock protein family A member 5; IKE, imidazole ketone erastin; LONP1, lon peptidase 1; MAPK, mitogen-activated protein kinase; NFS1, human mitochondrial cysteine desulfurase; PG, physcion 8-O-β-D-glucopyranoside; RB, retinoblastoma; S1R, Sigma-1 receptor; SAS, sultasalazine; SCID1, steryo-CoA desaturase 1; SLC7A11, solute carrier family 7 member A11; STAT3, signal transducer and activator of transcription 3; STYK1, serine thioredoxin tyrosine kinase 1; TAZ, transcription regulator 1; VHL, vov Hippel-Lindau.
Gene and Protein-Regulated Ferroptosis
Positive Regulators

Overexpression of some genes and proteins can promote ferroptosis in cancer cells. The level of DNAJ/Hsp40 homolog subfamily B member 6 (DNAJB6) is negatively correlated with lymph node metastasis in esophageal squamous cell carcinoma (ESCC) patients, and the overexpression of its isoform DNAJB6a is accompanied by remarkable reduction in the protein levels of GPX4 and phospho-AKT (p-AKT), thus DNAJB6a plays an anti-oncogenic role in ESCC progression via ferroptosis (212). Signal transducer and activator of transcription-3 (STAT3) can promote ferroptosis through activation of cathepsin B-mediated lysosomal cell death in PANC-1 and CFPAC-1 cells (170).

Loss of function of genes and proteins could change the sensitivity of cancer cells to ferroptosis. The loss of function of retinoblastoma (Rb) protein is significant during liver carcinogenesis, and the Rb-negative status of hepatocellular carcinoma (HCC) cells promotes ferroptosis on sorafenib treatment (163). Knockdown of high mobility group box 1 (HMGB1) decreases erastin-induced ROS generation via a iron-mediated lysosomal pathway in HL-60 cells expressing NRASQ61L (201).

Some genes and proteins can affect lipid metabolism and subsequently induce ferroptosis. Bromelain induces ferroptosis by inhibiting the proliferation of KRAS mutant colorectal cancer cells via ACSL4 (192). ADP-ribosylation factor 6 (ARF6) can sensitize gemcitabine-resistance pancreatic cancer cells to RSL3-induced lipid peroxidation by affecting the ACSL4 protein levels (172). Hypoxia-inducible transcriptional factor 2α (HIF-2α) selectively enriches PUFAs by activating the expression of the hypoxia-inducible lipid droplet-associated (HILPDA) protein and induces a ferroptosis-susceptible cell state in 786-O cells (208).

Several cellular signaling pathways are also involved in ferroptosis. Removal of the Hippo pathway effector transcription regulator 1 (TAZ) confers ferroptosis resistance, whereas overexpression of TAZS89A sensitizes cells to ferroptosis. TAZ promotes ferroptosis by regulating epithelial membrane protein 1 (EMPI) and NOX4 in renal cell carcinoma (207). Low levels of TAZ in chemo-resistant recurrent ovarian cancer are responsible for reduced ferroptosis susceptibility (203). Blockade of MAPK signaling similarly protects cells from ferroptosis, whereas NSCLC with sustained MAPK activation is likely to respond to ferroptosis following cystine depletion (206).

Negative Regulators

Many genes and proteins can protect cancer cells from ferroptosis. The sigma-1 receptor (SIR) protects HCC cells against sorafenib, while knockdown of SIR could induce ferroptosis by blocking the expression of GPX4 (164). The human mitochondrial cysteine desulfurase (NFS1) is highly expressed in well-differentiated lung adenocarcinoma and protects cells from ferroptosis (182). CDGSH iron sulfur domain 1 (CISD1), an iron-containing outer mitochondrial membrane protein, negatively regulates erastin-induced ferroptosis in HepG2 and Hep3B cells by inhibition of mitochondrial lipid peroxidation in a GPX4-independent manner (168). Overexpression of the CISD2 gene has been shown to confer resistance to HN-6 and HN-10 cells against SAS-induced ferroptosis, while silencing CISD2 could reverse SAS-resistant cells to a ferroptotic state with increased levels of lipid ROS and mitochondrial Fe^{2+} (190).

Some genes and proteins hinder ferroptosis; however, ferroptosis can occur when these are suppressed. NRF2 can upregulate cystathionine β-synthase (CBS) to confer resistance to erastin-induced ferroptosis in ovarian cancer cells (204), however inhibition of CBS can trigger ferroptosis in HCC (167). Inhibition of Lon peptidase 1 (LONP1) could contribute to ferroptosis of PANC-1 cells by activating the NRF2/KEAP1 signaling pathway and upregulating GPX4 expression (175). Heat shock protein family A member 5 (HSPA5) can upregulate the expression and activity of GPX4 to prevent dihydroartemisinin-induced ferroptosis in glioma (176). Inhibition of glucose-regulated protein 78 (GRP78), one of the most active molecular chaperone components in the ER of cancer cells, could enhance the effect of artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells (174). Growth/differentiation factor 15 (GDF15) knockdown has been shown to promote erastin-induced ferroptosis in MGC803 cells by attenuating SLC7A11 expression and subsequently decreasing intracellular GSH levels (179).

Some genes and proteins can prevent ferroptosis via affecting lipid metabolism. EGLN1/c-Myc directly activates the expression of lymphoid-specific helicase (LSH) by inhibiting HIF-1α, then LSH as an oncogene epigenetically increases the expression level of lipid metabolic genes that inhibit ferroptosis in lung cancer (183). Reconstitution of the functional vov Hippel-Lindau (VHL) gene prevents ferroptosis by reverting cells back to an oxidative metabolism and increasing fatty acid degradation through β-oxidation (209). Steroyl-CoA desaturase 1 (SCD1), the rate-limiting enzyme of MUFA synthesis, is highly expressed in ovarian cancer tissues and cell lines, and overexpression of SCD1 could protect cells from ferroptosis (205).

Posttranslational modifications can also regulate ferroptosis. O-linked β-N-acetylglucosamine glycosylation of c-JUN antagonizes ferroptosis by inhibiting GSH synthesis in BEL-7402 and SMMC-7721 cells (165). Nedd4 ubiquitylates voltage-dependent anion channels 2/3 (VDAC2/3) and degrades them to suppress erastin-induced ferroptosis in melanoma cells (199).

Several genes and proteins related to ferroptosis can be utilized as prognostic markers. G12D is the most frequent mutation in KRAS (referred as KRASG12D), and it is confirmed that KRASG12D could be released from PDAC cells succumbing to autophagy-dependent ferroptosis, and then KRASG12D causes macrophages to switch to an M2-like pro-tumor phenotype via STAT3-dependent fatty acid oxidation and it is also found that high KRASG12D expression in macrophages is correlated with poor survival in PDAC patients (173). High expression of Serine Threonine Tyrosine kinase 1 (STYK1) predicts poorer prognosis and is related to high levels of GPX4 in NSCLC (184).
RNA-Regulated Ferroptosis

Many microRNAs (miRNAs) can protect cancer cells from ferroptosis. miRNA-522, regulated by heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1), is secreted from cancer-associated fibroblasts and packed into exosomes, leading to chemo-resistance through targeting 15-LOX and decreasing ROS accumulation in gastric cancer cells (196). The inhibitory effect of miRNA-103a-3p on GLS2 is downregulated to promote ferroptosis and anti-tumorigenesis on phycion 8-O-β-glucopyranoside (PG) treatment (194). miRNA-9 can suppress ferroptosis by inhibiting ATF4 in vitro (197). miRNA-137 negatively regulates ferroptosis by directly targeting SLC1A5 to decrease glutamine uptake and MDA accumulation (198). Nonetheless, there are also some miRNAs that promote ferroptosis; for instance, miRNA-214-3p could promote ferroptosis by inhibiting ATF4 in vitro and in vivo (161).

A few long non-coding RNAs (lncRNAs) may also regulate ferroptosis. Erastin could upregulate the lncRNA GABPB1-AS1, which could downregulate the level of GABPB1 by blocking GABPB1 translation, leading to the downregulation of peroxiredoxin-5 and suppression of the cellular anti-oxidant capacity, and high expression of GABPB1 has been correlated with poor prognosis in HCC patients (166). The lncRNA LINCO0336 is upregulated in lung cancer and functions as an inhibitor of ferroptosis in carcinogenesis by interacting with ELAV-like RNA-binding protein 1, which acts as a novel regulator of ferroptosis (185).

Several circular RNAs (circRNAs) might participate in the ferroptosis of cancer cells. Levels of circRNA TTBK2 and integrin subunit 8 (ITGB8) are upregulated in glioma tissues and cells with downregulated miRNA-761 levels, and circRNA TTBK2 regulates cell proliferation, invasion, and ferroptosis via the miRNA-761/ITGB8 axis (180). circRNA 0008035, which is upregulated in gastric cancer tissues and cells, promotes the growth of gastric cancer cells and represses ferroptosis by upregulating eukaryotic initiation factor 4A1 (EIF4A1) through sponging miRNA-599 (195).

CONCLUSION AND PERSPECTIVE

In recent years, numerous studies have been conducted to study ferroptosis in cancers, and several anti-tumor drugs (such as sorafenib, SAS, altetamin) have been approved by the FDA. However, many unsolved issues regarding ferroptosis still exist. What is the executor of ferroptosis in cancer? Which is the main pathway of lipid peroxidation in ferroptosis, the nonenzymatic pathway or enzymatic one? Does there exist another mechanism of ferroptosis resistance? What is the likelihood that the ferroptosis-related anti-tumor drugs could be used in clinical settings, such as post-operation, chemo-resistance, or radioresistance instances? What are the potential adverse effects of ferroptosis-related anti-tumor drugs? Could the administration of ferroptosis-related anti-tumor drugs be combined with immunotherapy? The research on ferroptosis is still in its infancy, and more studies are needed to comprehensively explore the mechanism of ferroptosis in various cancers.

AUTHOR CONTRIBUTIONS

ZS and CS designed and conceptualized the review. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

Thanks to editor Maria Ida Amabile for her help. This work was supported by the National Natural Science Foundation of China (NSFC) (no. 81572529, 81972373) and the Scientific Research Foundation for Advanced Talents, Xiang’an Hospital of Xiamen University (no. PM201809170001). In addition, ZS especially wishes to thank his wife Meiying Huang and his parents who have given him strong spiritual and financial support during his hard times.

REFERENCES

1. Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell (2019) 35:830–49. doi: 10.1016/j.ccell.2019.04.002
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:1–41. doi: 10.3322/caac.21660
3. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 149:1060–72. doi: 10.1016/j.cell.2012.05.042
4. Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoygenases drives ferroptosis. Proc Natl Acad Sci USA (2016) 113:E4966–4975. doi: 10.1073/pnas.1603244113
5. Do Van B, Gouel F, Jonneaux A, Timmerman K, Gele P, Petraut M, et al. Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis (2016) 94:169–78. doi: 10.1016/j.nbd.2016.05.011
6. Guiney SJ, Adlard PA, Bush AI, Finkelstein DI, Ayton S. Ferroptosis and cell death mechanisms in Parkinson’s disease. Neurochem Int (2017) 104:34–48. doi: 10.1016/j.neuint.2017.01.004
7. Cong L, Dong X, Wang Y, Deng Y, Li B, Dai R. On the role of synthesized hydroxylated chalcones as dual functional amyloid-beta aggregation and ferroptosis inhibitors for potential treatment of Alzheimer’s disease. Eur J Med Chem (2019) 166:11–21. doi: 10.1016/j.ejmech.2019.01.039
8. Yan N, Zhang J. Iron Metabolism, Ferroptosis, and the Links With Alzheimer’s Disease. Front Neurosci (2019) 13:1443. doi: 10.3389/fnins.2019.01443
9. Cotticelli MG, Xia S, Lin D, Lee T, Terrab L, Wipf P, et al. Ferroptosis as a Novel Therapeutic Target for Friedreich’s Ataxia. J Pharmacol Exp Ther (2019) 369:47–54. doi: 10.1124/jpet.118.252759
10. Mi Y, Gao X, Xu H, Cui Y, Zhang Y, Gou X. The Emerging Roles of Ferroptosis in Huntington’s Disease. Neuromolecular Med (2019) 21:110–9. doi: 10.1007/s12017-018-8518-6
11. Park SJ, Cho SS, Kim KM, Yang JH, Kim JH, Jeong EH, et al. Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol (2019) 379:114665. doi: 10.1016/j.taap.2019.114665
12. Deng G, Li Y, Ma S, Gao Z, Zeng T, Chen L, et al. Caveolin-1 dictates ferroptosis in the execution of acute immune-mediated hepatic damage by...
attenuating nitrogen stress. *Free Radic Biol Med* (2020) 148:151–61. doi: 10.1016/j.freeradbiomed.2019.12.026

13. Magtanong L, Diao SJ. Ferroptosis and Brain Injury. *Dev Neurosci* (2018) 40:382–95. doi: 10.1159/000489622

14. Zhang Z, Wu Y, Yuan S, Zhang P, Zhang J, Li H, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. *Brain Res* (2018b) 1701:112–25. doi: 10.1016/j.brainres.2018.09.012

15. Kenny EM, Fidan E, Yang Q, Anthomythu TS, New LA, Meyer EA, et al. Ferroptosis Contributes to Neuronal Death and Functional Outcome After Traumatic Brain Injury. *Crit Care Med* (2019) 47:410–8. doi: 10.1097/CCM.0000000000003555

16. Yoo D, Zhang H, Hao J, Duan HQ, Zhao CX, Sun C, et al. Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis. *Neural Regener Res* (2019) 14:532–41. doi: 10.4103/1673-5374.245480

17. Zhang Y, Sun C, Zhao C, Hao J, Zhang Y, Fan B, et al. Ferroptosis inhibitor SRS 16–86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. *Brain Res* (2019a) 1706:48–57. doi: 10.1016/j.jbrained.2018.10.023

18. Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco S, Cannata-Ortiz P, Sanchez-Nimo MD, et al. Ferroptosis, but Not Necroptosis, Is Important in Nephrotic Folic Acid-Induced AKI. *J Am Soc Nephrol* (2017) 28:218–29. doi: 10.1681/ASN.2015121376

19. Hu Z, Zhang H, Yang SK, Wu X, He D, Cao K, et al. Emerging Role of Ferroptosis in Acute Kidney Injury. *Oxid Med Cell Longev* (2019) 2019:8010614. doi: 10.1155/2019/8010614

20. Hu Z, Zhang H, Yi B, Yang S, Liu J, Hu J, et al. VDR activation attenuates cisplatin induced AKI by inhibiting ferroptosis. *Cell Death Dis* (2020) 11:73. doi: 10.1038/s41419-020-2256-z

21. Sui M, Jiang X, Chen J, Yang H, Zhu Y. Magnesium isoglycurhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. *BioMed Pharmacother* (2018a) 106:125–33. doi: 10.1016/j.biopha.2018.06.060

22. Kong Z, Liu R, Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway. *BioMed Pharmacother* (2019) 109:2043–53. doi: 10.1016/j.biopha.2018.11.030

23. Li X, Duan L, Yuan S, Zhuang X, Qiao T, He J. Ferroptosis inhibitor alleviates Radiation-induced lung fibrosi (RIFL) via down-regulation of TGF-beta. *J Inflammation (Lond)* (2019) 16:11. doi: 10.1186/s12950-019-0216-0

24. Liu B, Zhao C, Li H, Chen X, Ding Y, Xu S. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. *Biochem Biophys Res Commun* (2018) 497:233–40. doi: 10.1016/j.bbrc.2018.02.061

25. Chen X, Hu S, Zhao C, Liu B. Role of TLRA4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure. *Biochem Biophys Res Commun* (2019a) 516:37–43. doi: 10.1016/j.bbrc.2019.06.015

26. Ng SW, Norwitz SG, Norwitz ER. The Impact of Iron Overload and Ferroptosis on Reproductive Disorders in Humans: Implications for Preeclampsia. *Int J Mol Sci* (2019) 20:3283. doi: 10.3390/ijms20133283

27. Ng SW, Norwitz SG, Taylor HS, Norwitz ER. Endometriosis: The Role of Iron Overload and Ferroptosis. *Reprod Sci* (2020) 27:1383–90. doi: 10.1007/s12015-020-00164-z

28. Zhang H, He Y, Wang XJ, Chen MH, Xu JJ, Jiang MH, et al. miR-30-5p-mediated ferroptosis of trophoblasts is implicated in the pathogenesis of preeclampsia. *Redox Biol* (2020b) 29:101402. doi: 10.1016/j.redox.2019.101402

29. Li L, Cao F, Yin HL, Huang ZL, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. *Cell Death Dis* (2020b) 11:88. doi: 10.1038/s41419-020-2298-2

30. Eagle H. The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture. *J Exp Med* (1955) 102:37–48. doi: 10.1084/jem.102.1.37

31. Eagle H. Amino acid metabolism in mammalian cell cultures. *Science* (1959) 130:432–7. doi: 10.1126/science.130.3373.432

32. Eagle H, Piez KA, Oyama VI. The biosynthesis of cystine in human cell cultures. *J Biol Chem* (1961) 236:1425–8. doi: 10.1016/S0021-9258(18)64190-0
Doll, S. Freitas, FP, Shah R, Aldrovandi M, Da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. *Nature* (2019) 575:693–8. doi: 10.1038/s41586-019-1707-0

Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. *Redox Biol* (2017) 11:254–62. doi: 10.1016/j.redox.2016.12.010

Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. *Nature* (2015) 520:567–62. doi: 10.1038/nature14344

Ou Y, Wang SL, Li D, Chu B, Gu W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. *Proc Natl Acad Sci USA* (2016) 113:E6806–12. doi: 10.1073/pnas.1607512113

Tarangelo A, Magtanong L, Bieging-Rolett KT, Li Y, Ye J, Attardi LD, et al. p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. *Cell Rep* (2018) 22:569–75. doi: 10.1016/j.celrep.2017.12.077

Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. *J Biol Chem* (1999) 274:11455–8. doi: 10.1074/jbc.274.11.1455

Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife* (2014) 3:e02523. doi: 10.7554/elife.02523

Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. *Cell Chem Biol* (2019b) 26:623–63 e629. doi: 10.1016/j.chembiol.2019.01.008

Gout PW, Buckley AR, Simms CR, Bruchovskiy N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. *Leukemia* (2001) 15:1633–40. doi: 10.1038/sj.leu.2402338

Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Maziere JC, Chauffert B, et al. Iron-dependent death of cellular carcinoma cells exposed to sorafenib. *Int J Cancer* (2013) 133:1732–42. doi: 10.1002/ijc.28159

Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. *Anticancer Res* (2014) 34:6417–22.

Li Y, Yan H, Xu X, Liu H, Wu C, Zhao L. Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nr2f2/CoX pathway. *Oncol Lett* (2020c) 19:233–38. doi: 10.3892/ol.2019.11066

Felley-Bosco E, Gray SG. Mesothelioma Driver Genes, Ferroptosis, and Therapy. *Front Oncol* (2019) 9:1318. doi: 10.3389/fonc.2019.01318

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Lachaier E, Louandre C, Godin C, Saidak Z, Baert M, Diouf M, et al. Sorafenib induces ferroptosis in human cancer cells originating from different solid tumors. *Anticancer Res* (2014) 34:6417–22.

Yonezawa M, Back SA, Gan X, Rosenberg PA, Volpe J]. Cystine deprivation induces oligodendrogial death: rescue by free radical scavengers and by a diffusible giall factor. *J Neurochem* (1996) 67:566–73. doi: 10.1111/j.1471-4159.1996.67020566.x

Hohenberger J, Ray K, Meyer K. The biology and chemistry of high-valent iron-oxo and iron-nitrido complexes. *Nat Commun* (2012) 3:720. doi: 10.1038/ncomms1718

Fenton HJH. Oxidation of tartaric acid in presence of iron. *J Chem Soc Trans* (1894) 65:899–910. doi: 10.1039/CT8946500899

Haber F, Weiss J. Uber die Katalyse des Hydroperoxydes. *Naturwissenschaften* (1932) 20:948–50. doi: 10.1007/BF01504715

Crielard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. *Nat Rev Drug Discovery* (2017) 16:400–23. doi: 10.1038/nrd.2016.248

Zhou L, Zhao B, Zhang L, Wang S, Dong D, Lv H, et al. Alterations in Cellular Iron Metabolism Provide More Therapeutic Opportunities for Cancer. *Int J Mol Sci* (2018) 19:1545. doi: 10.3390/ijms19051545

Hubert N, Hentze MW. Previously uncharacterized isoforms of divergent metal transporter (DMT)-1: implications for regulation and cellular function. *Proc Natl Acad Sci USA* (2002) 99:12345–50. doi: 10.1073/pnas.192423399

67. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of ferritin. *Nature* (2001) 409:198–201. doi: 10.1038/35051594

68. Shimizu D, Nishizawa M, Kitamoto S, Matsuoka K, Ooi S, et al. TUMR1 and TUMR2 regulate ferroptosis through inhibition of mitochondrial dysfunction linking inflammation and colon cancer. *Proc Natl Acad Sci USA* (2017) 114:E9608–17. doi: 10.1073/pnas.1712946114

69. Guo W, Zhang S, Chen Y, Zhang D, Yuan L, Cong H, et al. An important role of the hsp90-ferritinoprotein signaling in affecting tumor growth and metastasis. *Acta Biochim Biophys Sin* (Shanghai) (2015) 47:703–15. doi: 10.1093/abbs/gmv063

70. Zhang C, Wei Z, Shokh ZA. Suppressing of ferroptosis expression by cadmium stimulates proliferation, EMT, and migration in triple-negative breast cancer cells. *Toxicol Appl Pharmacol* (2018) 356:363–43. doi: 10.1016/j.taap.2018.07.017

71. Wang Y, Yu L, Ding J, Chen Y. Iron Metabolism in Cancer. *Int J Mol Sci* (2018b) 20:9725. doi: 10.3390/ijms200109725

72. Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. *Protein Cell* (2015) 6:688–90. doi: 10.1007/s13238-014-0119-z

73. Hishikawa D, Hashidate T, Shimizu T, Shindou H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. *J Lipid Res* (2014) 55:799–807. doi: 10.1194/jlr.R046094

74. Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. *ACS Chem Biol* (2015) 10:1604–9. doi: 10.1021/acschembio.5b00245

75. Reis A, Spickett CM. Chemistry of phospholipid oxidation. *Biochim Biophys Acta* (2012) 1818:2374–87. doi: 10.1016/j.bbamem.2012.02.002

76. Cheng Z, Li Y. What is responsible for the initiating chemistry of iron-mediated lipid peroxidation: an update. *Chem Rev* (2007) 107:748–66. doi: 10.1021/cr040077w
Scheerer P, Borchert A, Krauss N, Wessner H, Gerth C, Hohne W, et al.

Weiwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, Macpherson L, et al.

Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, et al.

Frontiers in Oncology | www.frontiersin.org April 2021 | Volume 11 | Article 579286

Shi et al. Ferroptosis in Cancers

express mutant RAS. Bioorg Med Chem Lett (2012) 22:1822–6. doi: 10.1016/j.bmcl.2011.09.047

Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci (2016) 73:2195–209. doi: 10.1007/s00018-016-2194-1

Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol (2016) 12:497–503. doi: 10.1038/nchembio.2079

Gaschler MM, Andia AA, Liu H, Coska JM, Hurlocker B, Vaiana CA, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol (2018) 14:507–7. doi: 10.1038/s41555-018-0031-6

Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet (2004) 363:892–4. doi: 10.1016/S0140-6736(04)15739-9

Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer (2005) 5:930–42. doi: 10.1038/nrc1751

Viemannathan VS, Ryan MJ, Dhuruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature (2017) 547:453–7. doi: 10.1038/nature23007

Qi X, Kim DH, Yoon YS, Kim SK, Cai DQ, Teng YC, et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett (2010) 199:277–87. doi: 10.1016/j.toxlet.2010.09.010

Hadian K. Ferroptosis Suppressor Protein 1 (FSPI1) and Coenzyme Q10 Cooperatively Suppress Ferroptosis. Biochemistry (2020) 59:637–8. doi: 10.1021/acs.biochem.0c00030

Mol P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA (1994) 91:9926–30. doi: 10.1073/pnas.91.21.9926

Jamillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev (2013) 27:2179–91. doi: 10.1101/gad.225680.113

Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 recruits Nhe2 through binding to ETFGE and Dlg motif characterization of the two-site molecular recognition model. Mol Cell Biol (2006) 26:2887–900. doi: 10.1128/MCB.26.8.2887-2900.2006

Anandan A, Dodson M, Schmidlin CJ, Liu P, Zhang DD. Breakdown of an Ironclad Defense System: The Critical Role of Nrf2 in Mediating Ferroptosis. Cell Chem Biol (2020) 27:436–47. doi: 10.1016/j.chembiol.2020.03.011

Shin D, Kim EH, Lee J, Roh JL. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med (2018) 129:454–62. doi: 10.1016/j.freeradbiomed.2018.10.426

Itoh K, Igarashi K, Hayashi N, Nishizawa M, Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol Cell Biol (1995) 15:4184–93. doi: 10.1128/MCB.15.8.4184

Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukumizu A, Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells (2001) 6:857–68. doi: 10.1046/j.1097-3162.2001.00469.x

Zhu M, Fahl WE. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun (2001) 289:212–9. doi: 10.1006.bbrc.2001.5944

Nioi P, Nguyen T, Sherratt PJ, Pickert CB. The carboxy-terminal Neh3 domain of NF2 is required for transcriptional activation. Mol Cell Biol (2005) 25:10895–906. doi: 10.1128/MCB.25.24.10895-10906.2005

Chowdhry S, Zhang Y, McMahan M, Sutherland C, Cuadrado A, Hayes JD. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene (2013) 32:3765–81. doi: 10.1038/onc.2012.388

Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, et al. RXRalpha inhibits the FINO2 mediated ferroptosis in head and neck cancer. Cell Mol Life Sci (2020) 77:132–46. doi: 10.1007/s00018-020-09001-8

Gagliardi M, Cotella D, Santoro C, Cora D, Barlev NA, Piacentini M, et al. Aldo-keto reductases protect metastatic melanoma from ER stress-dependent ferroptosis. Cell Death Dis (2019) 10:902. doi: 10.1038/s41419-019-2143-7
140. Hubner RH, Schwartz JD, De Bishnu P, Ferris B, Ombreg L, Mezey JG, et al. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. *Mol Med* (2009) 15:203–19. doi: 10.2119/molmed.2008.00130

141. Harada N, Kanayama M, Maruyama A, Yoshida A, Tazumi K, Hosoya T, et al. Nrf2 regulates ferroportin 1-mediated iron eflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages. *Arch Biochem Biophys* (2011) 508:101–9. doi: 10.1016/j.ab.2011.02.001

142. Agyeman AS, Chaerkady R, Shaw PG, Davidson NE, Visvanathan K, Pandey A, et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. *Breast Cancer Res Treat* (2012) 132:175–87. doi: 10.1007/s10549-011-1536-9

143. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. *Nucleic Acids Res* (2012) 40:7416–29. doi: 10.1093/nar/gks409

144. Campbell MR, Karaca M, Adamski KN, Chorley BN, Wang X, Bell DA. Novel hematopoietic target genes in the NRF2-mediated transcriptional pathway. *Oxid Med Cell Longev* (2013) 2013:120305. doi: 10.1155/2013/120305

145. Gai C, Yu M, Li Z, Wang Y, Ding D, Zheng J, et al. Acetaminophen stimulates erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small cell lung cancer. *J Cell Physiol* (2020) 235:3329–39. doi: 10.1002/jcp2.29221

146. Thimmulappa RK, Mai KH, Srisuma S, Kessler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. *Cancer Res* (2002) 62:196–203.

147. Cho HY, Gladwell L, Wang X, Chorley B, Bell D, Reddy SP, et al. O-GlcNAcylation of c-Jun antagonizes ferroptosis via inhibiting GSH synthesis in liver cancer. *Cell Signal* (2019c) 63:109384. doi: 10.1016/j.cellsig.2019.109384

148. Qiu W, Li Z, Xia L, Dai J, Zhang Q, Wu C, et al. LncRNA GABPB1-ASI and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells. *Sci Rep* (2019) 9:16185. doi: 10.1038/s41598-019-52387-8

149. Wang L, Cai H, Hu Y, Liu F, Huang S, Zhou Y, et al. A pharmacological probe identifies cystathionine beta-synthase as a new negative regulator for ferroptosis. *Cell Death Dis* (2018a) 9:1005. doi: 10.1038/s41419-018-1063-2

150. Yuan H, Li X, Zhang X, Kang R, Tang D. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. *Biochem Biophys Res Commun* (2016) 478:838–44. doi: 10.1016/j.bbrc.2016.08.034

151. Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. *Oncosience* (2015) 2:517–32. doi: 10.18632/oncoscience.160

152. Gao H, Bai Y, Jia Y, Zhao Y, Kang R, Tang D, et al. Ferroptosis is a lysosomal cell death process. *Biochem Biophys Res Commun* (2018) 503:1550–6. doi: 10.1016/j.bbrc.2018.07.078

153. Yamaguchi Y, Kasukabe T, Kumakura S. Pipelolinumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. *Int J Oncol* (2018) 52:1011–22. doi: 10.3892/ijo.2018.4239

154. Ye Z, Hu Q, Zhuo Q, Zhu Y, Fan G, Liu M, et al. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic ductal adenocarcinoma cells. *J Cancer Res* (2020) 10:1182–93.

155. Bai T, Lei P, Zhou H, Liang R, Zhang X, Wang W, et al. Sigma-1 receptor protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells. *Anticancer Res* (2020) 40:463–470. doi: 10.21873/ajpcr.26577

156. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. *Cold Spring Harb Perspect Biol* (2010) 2:a001107. doi: 10.1186/cshperspect.a001107

157. Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. *J Mol Biol* (2017) 429:1595–1606. doi: 10.1016/j.jmb.2017.03.030

158. Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. *Nat Rev Cancer* (2018) 18:89–102. doi: 10.1038/nrc.2017.109
Biochem Biophys Res Commun (2020a) 526:293–9. doi: 10.1016/j.bbrc.2020.03.077

180. Zhang HY, Zhang BW, Zhang ZB, Deng QJ. Circular RNA TTBK2 regulates cell proliferation, invasion and ferroptosis via miR-761/ITGB8 axis in glioma. Eur Rev Med Pharmacol Sci (2020c) 24:2585–600. doi: 10.26355/eurrev_202003_20528

181. Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S, et al. Erinian, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Sigal Transduct Target Ther (2020b) 5:51. doi: 10.1038/s41392-020-0149-3

182. Alvarez SW, Sviderskiy VO, Terzi EM, Papagiannakopoulos T, Moreira AL, Adams S, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis. Nature (2017) 551:639–43. doi: 10.1038/nature24637

183. Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, et al. EGLN1/c-Myc Induced Lymphoid-Specific Helicase Inhibits Ferroptosis through Lipid Metabolic Gene Expression Changes. Theranostics (2017) 7:3293–305. doi: 10.7150/thno.19988

184. Lai Y, Zhang Z, Li J, Li W, Huang Z, Zhang C, et al. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma. Biochem Biophys Res Commun (2019) 519:659–66. doi: 10.1016/j.bbrc.2019.09.032

185. Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Dis (2019b) 26:2329–43. doi: 10.1038/s41418-019-0304-y

186. Lin YS, Shen YC, Wu CY, Tsai YY, Yang YH, Lin YY, et al. Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells. Front Pharmacol (2019) 10:1226. doi: 10.3389/fphar.2019.01226

187. Llabani E, Hicklin HY, Lee HY, Motika SE, Crawford LA, Weerapana E, et al. Compound in Dendrobium extract, inhibits lung cancer cell growth and induces ferroptosis associated with autophagy. Biochem Biophys Res Commun (2019) 516:1265–71. doi: 10.1016/j.bbrc.2019.06.070

188. Yang WH, Huang Z, Wu J, Ding CC, Murphy SK, Chi JT. A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. Mol Cancer Res (2020a) 18:79–90. doi: 10.1158/1541-7786.MCR-19-0691

189. Liu N, Lin X, Huang C. Activation of the reverse transsulfuration pathway through NR2F2/CBS confers erastin-induced ferroptosis resistance. Br J Cancer (2020) 122:2729–92. doi: 10.1038/s41416-019-0660-x

190. Ye FH, Chai WW, Xie M, Yang MH, Yu Y, Cao LZ, et al. HMGB1 regulates endogenous RNA. Theranostics (2020a) 10:334. doi: 10.7150/thno.21005

191. Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, et al. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Dis (2018) 25:1457–72. doi: 10.1038/s41418-017-0053-8

192. Yang Y, Luo M, Zhang K, Zhang J, Gao T, Connell DO, et al. Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. Nat Commun (2020b) 11:433. doi: 10.1038/s41467-020-14324-x

193. Dong T, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med (2019) 131:356–69. doi: 10.1016/j.freeradbiomed.2018.12.011

194. Zhou Y, Huang ZX, Chen GQ, Sheng F, Zheng YS. Typhosildenafil prevents acute myeloid leukemia (AML) through suppressing proliferation and inducing ferroptosis associated with autophagy. Biochem Biophys Res Commun (2019) 516:1265–71. doi: 10.1016/j.bbrc.2019.06.070

195. Li C, Tian Y, Liang Y, Li Q. Circ_0008035 contributes to cell proliferation and apoptosis and induces ferroptosis of glioblastoma cells via downregulation of nuclear factor erythroid 2-related factor 2 signaling pathway. AntiCancer Drugs (2020a) 31:27–34. doi: 10.1097/CAD.0000000000000825

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Shi, Zhang, Zheng, Sun and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.